

Luxembourg, 14 June 2021

Scientific Committee on Consumer Safety (SCCS) Meeting of the Working Group on Methodologies

28 May 2021, Luxembourg

Minutes

1. Welcome and apologies, approval of the agenda and declaration of interests

The SCCS Chair welcomed the participants. Two apologies were received. The agenda was adopted without changes.

The minutes of the previous meeting held on 26 February 2021 were endorsed by written procedure by the WG members and published on the website: https://ec.europa.eu/health/scientific_committees/consumer_safety/minutes_wg_meetings_en

The Chair invited participants to declare any interest regarding matters on the agenda. None of the participants declared any interest conflicting with the matter on the agenda.

2. List of points discussed

<u>Presentation of the Chair reports from two external meetings: one on Threshold for</u> <u>Toxicological Concern (TTC) and one on Organ-on chip (OoC)</u>

The chair circulated her reports to the WG and presented a power point on OoC as an introduction to the session on thyroid function that followed this presentation. As OoC is new methodology which is not yet in the phase of being standardised and validated, the SCCS will closely follow developments in the field and may amend/revise their Notes of Guidance anytime it is needed. The content of the TTC workshop was also discussed and the conclusion was that the data presented for DNA-reactive carcinogens are supportive for the actual values taken up in the Notes of Guidance for genotoxic carcinogens.

Presentation by external speakers (internal session):

Internal presentations were made by representatives from Bayer pharma industry to update the experts of the SCCS with ongoing research in the field of thyroid function. This will be helpful in particular as the SCCS is going through safety evaluation of endocrine disrupting substances used in cosmetic products in which thyroid function is one of the items discussed in the dossiers.

Observers from Bayer participated in the meeting.

A discussion took place regarding the models developed and the results obtained as these are not validated yet, but could be an inspiration for decisions taken in a weight of evidence approach.

The SCCS stressed the importance to be kept informed about further developments and will continue to discuss internally. The presentation from Bayer was made available for the SCCS only. Posters presented earlier in international context are publicly available and not restricted to the SCCS.

Presentation by external speakers (open session):

Genotoxicity and carcinogenicity

Presentations were made by representatives from Cosmetics Europe (CoE) to update the experts of the SCCS with ongoing research in the field of genotoxicity and carcinogenicity. This could be helpful for later updating of the SCCS Notes of Guidance when considered necessary.

Observers from Cosmetics Europe and IFRA participated in the meeting.

A discussion took place regarding the validation progress of the assays presented as well as comments on the SCCS Notes of Guidance.

The SCCS stressed the importance to be kept informed about further developments and will continue to discuss these topics. The presentations from CoE were available for the SCCS only. Suggestions for eventual limited changes to be taken up in the SCCS Notes of Guidance will be considered by the SCCS when received and argumented.

3. Information from chairman/members/commission

/

4. Next meetings

To be confirmed.